Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Ryan on the COU-AA-302 Interim Analysis Results

June 11th 2012

Dr. Charles Ryan, from the UCSF Diller Family Comprehensive Cancer Center, on the COU-AA-302 Abiraterone Acetate Interim Analysis Results.

Dr. Shore Discusses the Enzalutamide AFFIRM Trial

June 8th 2012

Dr. Neal Shore, from the Atlantic Urology Clinics, Discusses the Enzalutamide (MDV3100) AFFIRM Trial

Dr. Taplin on Neoadjuvant Abiraterone and Leuprolide

June 8th 2012

Dr. Mary-Ellen Taplin, from Dana-Farber Cancer Institute, on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate

With Continuous Hormonal Therapy, Certain Men With Prostate Cancer Get Marked Boost in Survival

June 3rd 2012

Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.

Dr. Concepcion Discusses Prostate Cancer Therapies

May 31st 2012

Dr. Raoul Concepcion, from Urology Associates, PC, Nashville, TN, Discusses New Prostate Cancer Therapies.

Dr. Gomella on the Unique Attributes of Neoadjuvant Zytiga

May 30th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.

ï»¿Docetaxel in Combination With Novel Therapies in Prostate Cancer: Promising Phase III Trials Ongoing

May 29th 2012

To date, no studies of novel therapies combined with docetaxel and prednisone have demonstrated improvement in their designated endpoints. However, several promising combination trials are ongoing.

ï»¿Targeted Focal Therapy Emerges as Alternative to Active Surveillance or Definitive Treatment

May 25th 2012

Focal therapy offers some men with localized prostate cancer a solution between active surveillance and definitive treatment with surgery and/or radiation.

Dr. Sieber on Managing Bone Health After ADT

May 25th 2012

Dr. Paul Sieber, from the Urological Association of Lancaster, on Managing Bone Health After the Introduction of ADT.

Prostate Cancer Screening: A Q&A With Oliver Sartor, MD, and Leonard G. Gomella, MD

May 24th 2012

Oliver Sartor, MD, and Leonard G. Gomella, MD, discuss multiple topics involved with prostate-specific antigen (PSA) screening, including PSA velocity, guidelines, and cutoff age.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Federal Panel Rejects Routine Prostate Cancer Screening

May 22nd 2012

The USPSTF has made a final recommendation against routine screening for prostate cancer in asymptomatic males through PSA testing.

Dr. Gomella on the Impact of the New USPSTF PSA Rating

May 22nd 2012

Dr. Leonard Gomella, form the Jefferson Kimmel Cancer Center, on the Impact of the New USPSTF PSA Rating.

Dr. Oliver Sartor Discusses PSA Screening

May 22nd 2012

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Prostate-Specific Antigen (PSA) Screening

Dr. Gomella Discusses the IMPACT Trial Survival Benefit

May 21st 2012

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on the Provenge IMPACT Trial Survival Benefit

Politics and Science Intersect in PSA Screening

May 21st 2012

Leonard G. Gomella, MD, discusses the public policy and medical implications of the US Preventive Services Task Force's draft recommendation on PSA screening.

UK Advisory Group Reverses Decision on Abiraterone; Drug Expected to Be Funded

May 18th 2012

The prostate cancer drug abiraterone acetate is expected be provided for patients through England's publicly funded healthcare system after NICE reversed its initial recommendation.

Dr. Goy on Neoadjuvant Hormonal Therapy Plus Zytiga

May 18th 2012

Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga

Neoadjuvant Zytiga Helps Eliminate Some Patients' Prostate Tumors

May 16th 2012

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

Dr. Gomella on Neoadjuvant Hormonal Therapy Plus Zytiga

May 16th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate